Escitalopram for the treatment of major depression and anxiety disorders (Q37139768)

18 August 2017

1 reference

title

Escitalopram for the treatment of major depression and anxiety disorders (English)

1 reference

18 August 2017

1 reference

Cyril Höschl

1

1 reference

18 August 2017

Jaromír Svestka

series ordinal

2

1 reference

18 August 2017

publication date

1 April 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

537-552

1 reference

Escitalopram versus citalopram: the surprising role of the R-enantiomer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram and citalopram: the unexpected role of the R-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The clinical pharmacokinetics of escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The pharmacokinetics of escitalopram in patients with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Antidepressant treatment and rodent aggressive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

R-citalopram prevents the neuronal adaptive changes induced by escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Executive dysfunction, heart disease burden, and remission of geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in the long-term treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram prevents relapse in older patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram therapy for major depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram and suicidality in adult depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Outcomes after supratherapeutic escitalopram ingestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram: a review of its use in the management of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram: a review of its use in the management of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Managing depressive and anxiety disorders with escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram prevents relapse of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

Escitalopram in the treatment of anxiety symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.4.537

21 January 2018

Identifiers

DOI

10.1586/14737175.8.4.537

1 reference

18 August 2017

1 reference